Publication Results (223)

• «
• 1
• 2
• 3
• 4
• 5
• 6
• »

• Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: an ecologic study

  Tadrous M, Elterman D, Khuu W, Mamdani MM, Juurlink DN, Gomes T. Can Urol Assoc J. 2018; 12(3):E142-5. Epub 2017 Dec 22.

• Medication use and kidney cancer survival: a population-based study

  Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Int J Cancer. 2018; 142(9):1776-85. Epub 2017 Dec 11.

• Prior authorization and Canadian public utilization of direct-acting oral anticoagulants

  Gao L, Tadrous M, Knowles S, Mamdani M, Paterson JM, Juurlink D, Gomes T. Healthc Policy. 2017; 13(2):68-78.

• Gabapentin, opioids and the risk of opioid-related death: a population-based nested case-control study

  Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. PLoS Med. 2017; 14(10):e1002396. Epub 2017 Oct 3.

• Impact of a graduated approach on opioid initiation and loss of earnings following workplace injury: a time series analysis

  Gomes T, Duesburry J, Theriault ME, Bain D, Singh S, Martins D, Juurlink D. J Occup Environ Med. 2017; 59(12):1197-201. Epub 2017 Oct 3.

• Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma

  Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, Mamdani MM, Juurlink DN, Gomes T. Ann Allergy Asthma Immunol. 2018; 120(1):59-65.e2. Epub 2017 Oct 3.

• Impact of injectable furosemide hospital shortage on congestive heart failure outcomes: a time series analysis

  Tan VS, Nash DM, McArthur E, Jain AK, Garg AX, Juurlink DN, Weir MA. Can J Cardiol. 2017; 33(11):1498-504. Epub 2017 Sep 12.

• Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada

  Gomes T, Juurlink DN, Mamdani MM, Paterson JM, van den Brink W. Drug Alcohol Depend. 2017; 179:416-23. Epub 2017 Aug 31.

• Medication use and kidney cancer risk: a population-based study

  Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ. Eur J Cancer. 2017; 83:203-10. Epub 2017 Jul 24.

• Pregabalin and heart failure: a population-based study

  Ho JM, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, Juurlink DN. Pharmacoepidemiol Drug Saf. 2017; 26(9):1087-92. Epub 2017 Jun 16.

• Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study

  Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Drug Saf. 2017; 40(10):887-93. Epub 2017 Jun 15.

• Critical appraisal of the application of propensity score methods in the urology literature

  Nayan M, Hamilton RJ, Juurlink DN, Finelli A, Kulkarni GS, Austin PC. BJU Int. 2017; 120(6):873-80. Epub 2017 Jun 13.

• A 1980 letter on the risk of opioid addiction

  Leung PTM, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN. N Engl J Med. 2017; 376(22):2194-5. Epub 2017 Jun 1.

• The value of complementing administrative data with abstracted information on smoking and obesity: a study in kidney cancer

  Nayan M, Hamilton RJ, Finelli A, Austin PC, Kulkarni GS, Juurlink DN. Can Urol Assoc J. 2017; 11(6):167-71.

• Macrolides, digoxin toxicity and the risk of sudden death: a population-based study

  Quinn KL, Macdonald EM, Gomes T, Mamdani MM, Huang A, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Drug Saf. 2017; 40(9):835-40. Epub 2017 Apr 18.

• Lipophilic β-blockers and suicide in the elderly

  Zipursky JS, Macdonald EM, Luo J, Gomes T, Mamdani MM, Paterson JM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. J Clin Psychopharmacol. 2017; 37(3):381-4. Epub 2017 Mar 23.

• Impact of unrestricted access to pregabalin on the use of opioids and other CNS-active medications: a cross-sectional time series analysis

  Kwok H, Khuu W, Fernandes K, Martins D, Tadrous M, Singh S, Juurlink DN, Gomes T. Pain Med. 2017; 18(6):1019-26. Epub 2017 Mar 6.

• Overdose risk in young children of women prescribed opioids

  Finkelstein Y, Macdonald EM, Gonzalez A, Sivilotti ML, Mamdani MM, Juurlink DN; Canadian Drug Safety And Effectiveness Research Network (CDSERN). Pediatrics. 2017; 139(3):e20162887. Epub 2017 Feb 21.

• Self-monitoring of blood glucose: impact of quantity limits in public drug formularies on provincial costs across Canada

  Knowles SR, Lee K, Paterson JM, Shah BR, Mamdani MM, Juurlink DN, Gomes T. Can J Diabetes. 2017; 41(2):138-42. Epub 2016 Dec 15.

• High-dose opioid prescribing and opioid-related hospitalization: a population-based study

  Spooner L, Fernandes K, Martins D, Juurlink D, Mamdani M, Paterson JM, Singh S, Gomes T. PLoS One. 2016; 11(12):e0167479.

• Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation

  Antoniou T, Macdonald EM, Yao Z, Hollands S. Gomes T, Tadrous M, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. CMAJ. 2017; 184(1):E4-10. Epub 2016 Nov 21.

• Association of a blood glucose test strip quantity-limit policy with patient outcomes: a population-based study

  Gomes T, Martins D, Tadrous M, Paterson JM, Shah BR, Tu JV, Juurlink DN, Chu A, Mamdani MM. JAMA Intern Med. 2017; 177(1):61-6. Epub 2016 Nov 7.

• Vasectomy and risk of prostate cancer: population based matched cohort study

  Nayan M, Hamilton RJ, Macdonald EM, Li Q, Mamdani MM, Earle CC, Kulkarni GS, Jarvi KA, Juurlink DN. BMJ. 2016; 355:i5546.

• Medication use and survival in diabetic patients with kidney cancer: a population-based cohort study

  Nayan M, Macdonald EM, Juurlink DN, Austin PC, Finelli A, Kulkarni GS, Hamilton RJ; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Pharmacol Res. 2016; 113(2016):468-74. Epub 2016 Sep 24.

• Varenicline and risk of self-harm: a nested case-control study

  Tadrous M, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. PLoS One. 2016; 11(9):e0163681.

• The appropriateness and persistence of testosterone replacement therapy in Ontario

  Martins D, Yao Z, Tadrous M, Shah BR, Juurlink DN, Mamdani MM, Gomes T; Ontario Drug Policy Research Network. Pharmacoepidemiol Drug Saf. 2017; 26(2):119-26. Epub 2016 Aug 16.

• Association between incretin-based drugs and the risk of acute pancreatitis

  Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P, Suissa S, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, LeLorier J, Levy AR, Sketris IS; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. JAMA Intern Med. 2016; 315(20):2211-20. Epub 2016 May 24.

• Metformin use and kidney cancer outcomes in patients with diabetes: a propensity score analysis

  Nayan M, Finelli A, Jewett MA, Juurlink DN, Austin PC, Kulkarni GS, Hamilton RJ. Clin Genitourin Cancer. 2017; 15(2):300-5. Epub 2016 Jun 23.

• Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study

  Foster PD, Camacho X, Vigod S, Yao Z, Juurlink DN, Paterson MJ, Mamdani MM, Martins D, Gomes T. CMAJ Open. 2016; 4(2):E292-7.

• Self-monitoring of blood glucose levels: evaluating the impact of a policy of quantity limits on test-strip use and costs

  Gomes T, Martins D, Tadrous M, Paterson JM, Shah BR, Juurlink DN, Singh S, Mamdani MM. Can J Diabetes. 2016; 40(5):431-5. Epub 2016 May 17.

• Interprovincial variation in antipsychotic and antidepressant prescriptions dispensed in the Canadian pediatric population

  Arora N, Knowles S, Gomes T, Mamdani MM, Juurlink DN, Carlisle C, Tadrous M. Can J Psychiatry. 2016; 61(12):758-65. Epub 2016 May 12.

• Repetition of intentional drug overdose: a population-based study

  Finkelstein Y, Macdonald EM, Hollands S, Sivilotti MLA, Hutson JR, Mamdani MM, Koren G, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Clin Toxicol (Phila). 2016; 54(7):585-9. Epub 2016 May 12

• Off-label use of inhaled tobramycin in Ontario, Canada

  Tadrous M, Khuu W, Paterson JM, Mamdani MM, Juurlink DN, Gomes T. Thorax. 2016; 71(9):862-4. Epub 2016 May 10.

• The characteristics of treated pulmonary arterial hypertension patients in Ontario

  Vaid HM, Camacho X, Granton JT, Mamdani MM, Yao Z, Singh S, Juurlink DN, Gomes T. Can Respir J. 2016; 2016:6279250. Epub 2015 Nov 27.

• Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study

  Tadrous M, Martins D, Lee K, Knowles S, Mamdani MM, Juurlink DN, Gomes T. Expert Rev Pharmacoecon Outcomes Res. 2016; 16(6):803-7.

• The influence of socioeconomic status on selection of anticoagulation for atrial fibrillation

  Sholzberg M, Gomes T, Juurlink DN, Yao Z, Mamdani MM, Laupacis A. PLoS One. 2016; 11(2):e0149142.

• Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study

  Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. BMJ. 2016; 352:i581.

• Novel oral anticoagulants and the risk of major hemorrhage in elderly patients with chronic kidney disease: a nested case-control study

  Harel Z, Mamdani M, Juurlink DN, Garg AX, Wald R, Yao Z, Gomes T. Can J Cardiol. 2016; 32(8):986.e17-22. Epub 2016 Jan 22.

• Opioid use and overdose: what we’ve learned in Ontario

  Gomes T, Juurlink DN. Healthc Q. 2016; 18(4):8-11.

• Professional pharmacy services and patient complexity: an observational study

  Ignacy TA, Camacho X, Mamdani M, Juurlink D, Paterson M, Gomes T. J Pharm Pharm Sci. 2015; 18(5):863-70.

• «
• 1
• 2
• 3
• 4
• 5
• 6
• »